Patents by Inventor David Hook
David Hook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786498Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.Type: GrantFiled: July 2, 2015Date of Patent: October 17, 2023Assignee: Novartis AGInventors: David Hook, Bin Hu, Florian Karl Kleinbeck, Ulrich Meier, Sibylle Mueller, Jean-Paul Mutz, Jan Schlomach, Paul Allen Sutton, Liladhar Murlidhar Waykole, Bernhard Wietfeld
-
Patent number: 11642315Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.Type: GrantFiled: September 28, 2018Date of Patent: May 9, 2023Assignee: Novartis AGInventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
-
Publication number: 20220202728Abstract: A formulation for injection moulding of a pharmaceutical carrier comprising 27-85% (w/w) of polyvinyl alcohol, and 10-60% (w/w) of a disintegration aid selected from maize starch, wheat starch, and combinations thereof; and optionally one or more excipients.Type: ApplicationFiled: April 1, 2020Publication date: June 30, 2022Inventors: Florian BECK, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef MOLL, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Maxime Thomas-Schrapp, Raphael TOBLER, Patrick Tritschler
-
Publication number: 20220175682Abstract: The present invention relates to methods of preparing pharmaceutical products, involving filling active pharmaceutical ingredient powders into pharmaceutical carriers with a vacuum assisted metering and filling device. The methods disclosed herein can be used in a continuous process, such as in a high-throughput process for producing a pharmaceutical product. The present invention further relates to a particular quality of the neat active pharmaceutical ingredient (API) HDM201, i.e. siremadlin, present as succinic acid co-crystal, which can be used in the methods of preparation of the present invention.Type: ApplicationFiled: April 2, 2020Publication date: June 9, 2022Inventors: Nicole BIERI, Elodia DI RENZO, David HOOK, Jennifer Claire HOOTON, Markus KRUMME, Steffen LANG, Franck MALLET, Massimo MORATTO, Joerg OGORKA, Jim PARKS, Dale W. PLOEGER, Norbert RASENACK, Hendrik SCHNEIDER, Lipa SHAH, Stefan STEIGMILLER, Gordon STOUT, Patrick TRITSCHLER, Fabian WEBER
-
Publication number: 20210123713Abstract: A gauge comprising an elongate rod and a head. The rod has an elongate axis. The head has a transverse dimension perpendicular to the elongate axis of the rod. The gauge has an insertion configuration and an inspection configuration, wherein the transverse dimension of the head is greater in the inspection configuration than in the insertion configuration. The head comprises two head portions each with a longitudinally-extending outer surface and a longitudinally-extending inner surface and, in the insertion configuration, the inner surfaces of the head portions are at least partly in abutment with each other. The gauge can be used in a method of measuring an internal dimension of a bore within a component.Type: ApplicationFiled: September 28, 2020Publication date: April 29, 2021Applicant: ROLLS-ROYCE plcInventors: Jonathan L. BURTON, David HOOK
-
Publication number: 20200315973Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.Type: ApplicationFiled: September 28, 2018Publication date: October 8, 2020Inventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
-
Publication number: 20200306198Abstract: A formulation for injection molding of a pharmaceutical carrier comprises 43.5-97% (w/w) of one or more polyethylene oxide polymer having a weight average molecular weight of MW 94,000-188,000; and optionally one or more excipients.Type: ApplicationFiled: September 28, 2018Publication date: October 1, 2020Inventors: Florian Beck, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef Moll, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Raphael Tobler, Patrick Tritschler
-
Publication number: 20200246272Abstract: A pharmaceutical carrier (20) comprises a lid part (22) and a bottom part (24), wherein at least one of the lid part (22) and the bottom part (24) has a first wall section (26, 30) with a thickness of 180-250 ?m, preferably 185-225 ?m, even more preferably 190-220 ?m, and most preferably about 215 ?m, and a second wall section (28, 32) with a thickness of 350-450 ?m, preferably 375-425 ?m, more preferably 390-410 ?m, and most preferably about 400 ?m. The first wall section (26) of the lid part (22) defines an entire top portion of the lid part (22). Alternatively or additionally thereto, the first wall section (30) of the bottom part (24) defines an entire bottom portion of the bottom part (24).Type: ApplicationFiled: September 28, 2018Publication date: August 6, 2020Inventors: Florian Beck, Hans de Waard, Sarah Gold, Stefan Hirsch, David Hook, Nikhil Kavimandan, Markus Krumme, Steffen Lang, Detlef Moll, Siddharthya Mujumdar, Anh-Thu Nguyen-Trung, Joerg Ogorka, Norbert Rasenack, Raphael Tobler, Patrick Tritschler
-
Publication number: 20180296519Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.Type: ApplicationFiled: July 2, 2015Publication date: October 18, 2018Applicant: Novartis AGInventor: David Hook
-
Patent number: 9802887Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: June 15, 2015Date of Patent: October 31, 2017Assignee: Novartis AGInventors: David Hook, Bernhard Riss, Jianguang Zhou, Yunzhong Li, Erhard Bappert
-
Patent number: 9403766Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.Type: GrantFiled: November 12, 2015Date of Patent: August 2, 2016Assignee: NOVARTIS AGInventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
-
Patent number: 9278908Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a g-amino-d-biphenyl-a-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: June 15, 2015Date of Patent: March 8, 2016Assignee: Novartis AGInventors: David Hook, Jianguang Zhou, Yunzhong Li, Jie Ku
-
Publication number: 20160060217Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.Type: ApplicationFiled: November 12, 2015Publication date: March 3, 2016Inventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
-
Patent number: 9227934Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.Type: GrantFiled: May 18, 2015Date of Patent: January 5, 2016Assignee: NOVARTIS AGInventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
-
Patent number: 9206116Abstract: The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, particularly in the preparation of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: February 20, 2015Date of Patent: December 8, 2015Assignee: NOVARTIS AGInventors: David Hook, Thomas Ruch, Bernard Riss, Bernhard Wietfeld, Gottfried Sedelmeier, Matthias Napp, Markus Bänziger, Steven Hawker, Lech Ciszewski, Liladhar Murlidhar Waykole
-
Publication number: 20150274650Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: ApplicationFiled: June 15, 2015Publication date: October 1, 2015Inventors: David Hook, Bernhard Riss, Jianguang Zhou, Yunzhong Li, Erhard Bappert
-
Publication number: 20150274642Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a g-amino-d-biphenyl-a-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: ApplicationFiled: June 15, 2015Publication date: October 1, 2015Inventors: David Hook, Jianguang Zhou, Yunzhong LI, Jie Ku
-
Publication number: 20150246881Abstract: The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.Type: ApplicationFiled: May 18, 2015Publication date: September 3, 2015Applicant: Novartis AGInventors: David Hook, Bernard Riss, Daniel Kaufmann, Matthias Napp, Erhard Bappert, Philippe Polleux, Jonathan Medlock, Antonio Zanotti-Gerosa
-
Patent number: 9085529Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a -amino- -biphenyl- -methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: August 22, 2011Date of Patent: July 21, 2015Assignee: Novartis AGInventors: David Hook, Bernhard Riss, Jianguang Zhou, Yunzhong Li, Erhard Bappert
-
Patent number: 9067883Abstract: The invention relates to a new process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a g-amino-d-biphenyl-a-methylalkanoic acid, or acid ester, backbone, such as N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or salt thereof.Type: GrantFiled: January 21, 2011Date of Patent: June 30, 2015Assignee: Novartis AGInventors: David Hook, Jianguang Zhou, Yunzhong Li, Jie Ku